Orexo AB - Asset Resilience Ratio
Orexo AB (ORX) has an Asset Resilience Ratio of 0.00% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ORX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2023)
This chart shows how Orexo AB's Asset Resilience Ratio has changed over time. See shareholders equity of Orexo AB for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Orexo AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Orexo AB market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Orexo AB maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Orexo AB Industry Peers by Asset Resilience Ratio
Compare Orexo AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Reyon Pharmaceutical Co Ltd
KO:102460 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Moberg Pharma AB (publ)
ST:MOB |
Drug Manufacturers - Specialty & Generic | 5.24% |
|
AptaBio Therapeutics Inc
KQ:293780 |
Drug Manufacturers - Specialty & Generic | 1.57% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Canopy Growth Corp
NASDAQ:CGC |
Drug Manufacturers - Specialty & Generic | 0.45% |
|
Zhejiang Nhu Co Ltd
SHE:002001 |
Drug Manufacturers - Specialty & Generic | 4.38% |
|
IOL Chemicals and Pharmaceuticals Limited
NSE:IOLCP |
Drug Manufacturers - Specialty & Generic | 13.27% |
|
Beijing Science Sun Pharmaceutical Co Ltd
SHE:300485 |
Drug Manufacturers - Specialty & Generic | 43.40% |
Annual Asset Resilience Ratio for Orexo AB (2005–2023)
The table below shows the annual Asset Resilience Ratio data for Orexo AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | Skr0.00 ≈ $0.00 |
Skr786.60 Million ≈ $84.65 Million |
-- |
| 2022-12-31 | 19.80% | Skr219.60 Million ≈ $23.63 Million |
Skr1.11 Billion ≈ $119.35 Million |
+19.81pp |
| 2015-12-31 | 0.00% | Skr-40.00K ≈ $-4.30K |
Skr1.02 Billion ≈ $109.37 Million |
-14.78pp |
| 2006-12-31 | 14.77% | Skr56.13 Million ≈ $6.04 Million |
Skr379.93 Million ≈ $40.89 Million |
-9.37pp |
| 2005-12-31 | 24.14% | Skr89.63 Million ≈ $9.65 Million |
Skr371.31 Million ≈ $39.96 Million |
-- |
About Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company i… Read more